A federal appeals court has restricted access to mifepristone, one of the most common medications used to end early pregnancies, by blocking its distribution through mail. The unanimous ruling Friday from the New Orleans-based 5th U.S. Circuit Court of Appeals requires that the drug be distributed only in person and at clinics, overruling federal Food and Drug Administration regulations that had allowed telehealth prescriptions to be mailed directly to patients.
The decision represents a significant shift in abortion policy since the overturning of Roe v. Wade in 2022. Louisiana Attorney General Liz Murrill sued the FDA last month, arguing that its regulations undermined her state's ban on abortions at all stages of pregnancy. The ruling affects all states, including those without abortion restrictions, and is expected to be appealed to the U.S. Supreme Court.
What the Left Is Saying
Abortion-rights advocates criticized the ruling as out of step with public opinion and scientific evidence. Fatima Goss Graves, president and CEO of the National Women's Law Center, called it "deeply out of step with both the public and fact-based science."
Telehealth providers who have been prescribing mifepristone across state lines said they would continue their efforts to maintain access. Dr. Angel Foster, who runs The Massachusetts Medication Abortion Project, stated that her organization would "do everything in our power to continue providing care to people in all 50 states." Several Democratic-led states have adopted so-called shield laws designed to protect providers who prescribe via telehealth from civil and criminal liability in states with abortion bans.
Abortion-rights supporters argue that medication abortions have helped maintain access despite state-level restrictions. Providers have suggested that availability through telehealth is a reason why the overall number of abortions in the U.S. has not fallen significantly since Roe was overturned in 2022.
What the Right Is Saying
Anti-abortion advocates celebrated the ruling as a major step forward. Louisiana Attorney General Liz Murrill, a Republican, called it a "victory for life" and argued that federal regulations had created an avenue for out-of-state prescribers to circumvent state law. "The regulation creates an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law," wrote Judge Kyle Duncan, who was appointed by President Donald Trump.
Marjene Dannenfelser, president of Susan B. Anthony Pro-Life America, praised the reversal of rules that had ended a longstanding requirement for in-person doctor's visits to obtain the pills. She expressed frustration with the Trump administration, saying: "It's shameful that the Trump administration's inaction has forced pro-life states to take their battle to the federal courts." Some anti-abortion advocates had criticized Trump for not taking executive action himself to block distribution of mifepristone.
What the Numbers Show
Mifepristone was approved by the FDA in 2000 as a safe and effective method for ending early pregnancies. It is typically used in combination with a second drug, misoprostol, which is not affected by Friday's ruling but is less effective when used alone.
Surveys have found that medication abortions account for the majority of all abortions administered in the United States. Approximately one in four abortions nationally are now prescribed via telehealth, according to data cited in court filings. The FDA approved another generic version of mifepristone under the Trump administration last year, a decision that frustrated some anti-abortion allies.
Since Roe v. Wade was overturned in 2022, abortion has appeared directly on state ballots in 17 states. Voters have sided with the abortion-rights position in 14 of those ballot questions.
The Bottom Line
The ruling marks a rare instance of a federal court overruling FDA scientific regulations and is expected to be appealed to the U.S. Supreme Court. Danco Laboratories, a mifepristone manufacturer and defendant in the lawsuit, has requested that the appeals court put its order on hold for one week while seeking relief from the nation's highest court.
The case could become a significant issue in upcoming midterm elections as both parties assess the political ramifications of restricted medication abortion access. The ruling is currently in effect while the legal battle continues through the courts, affecting how the drug is dispensed nationwide regardless of individual state laws on abortion.